Locoregional Treatments before Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study from the European Liver Transplant Registry
Rigshospitalet, Copenhagen, Denmark
Rigshospitalet, Copenhagen, Denmark
Hôpital Universitaire Paul Brousse, Villejuif, France
National Institute of Public Health, Copenhagen, Denmark
Molinette Hospital, Turin, Italy
Hospital Virgen del Rocio, Seville, Spain
Hôpital Universitaire Paul Brousse, Villejuif, France
University of Pisa Medical School Hospital, Pisa, Italy
Hôpital Pontchaillou, Rennes, France
Istituto Nazionale Tumori, Milan, Italy
Beaujon Hospital, Clichy, France
Hospital Clínic, Barcelona, Spain
Hospital Universitari de Bellvitge, Barcelona, Spain
S. Orsola Hospital, Bologna, Italy
King's College Hospital, London, United Kingdom
Hôpital Universitaire Paul Brousse, Villejuif, France
Henri Mondor Hospital, Créteil, France
Rigshospitalet, Copenhagen, Denmark.
Meeting: 2018 American Transplant Congress
Abstract number: B275
Keywords: Hepatocellular carcinoma
Session Information
Session Name: Poster Session B: Liver: Hepatocellular Carcinoma and Other Malignancies
Session Type: Poster Session
Date: Sunday, June 3, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Purpose
Locoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has shown to improve survival. However, effect of treatment types has not been investigated. We investigate the effect of types of locoregional treatment on survival after Ltx for HCC.
Methods
We investigated patients registered in the European Liver Transplant Registry (ELTR) database using multivariate Cox regression survival analysis.
Results
Information on locoregional therapy was registered in 4,978 of 23,124 patients and was associated with improved overall survival (hazard ratio (HR) 0.84 [0.73-0.96]) and HCC specific survival (HR 0.76 [0.59-0.98]). Radiofrequency ablation (RFA) was the one monotherapy associated with improved overall survival (HR 0.51 [0.40-0.65]). In addition, the combination of RFA and transarterial chemoembolization (TACE) improved survival as well (HR 0.74 [0.55-0.99]).
Conclusion
Adjusting for factors related to prognosis, disease severity and tumor aggressiveness, RFA was highly beneficial regarding overall and HCC specific survival. The effect may represent a selection of patients with favorable tumor biology. However, the treatment may be effective per se by halting tumor progression and inducing an immune response toward the cancer.
CITATION INFORMATION: Pommergaard H-.C., Rostved A., Adam R., Thygesen L., Salizzoni M., Bravo M., Cherqui D., De Simone P., Boudjema K., Mazzaferro V., Soubrane O., García-Valdecasas J., Prous J., Pinna A., O'Grady J., Karam V., Duvoux C., Rasmussen A. Locoregional Treatments before Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study from the European Liver Transplant Registry Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Pommergaard H-C, Rostved A, Adam R, Thygesen L, Salizzoni M, Bravo M, Cherqui D, Simone PDe, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas J, Prous J, Pinna A, O'Grady J, Karam V, Duvoux C, Rasmussen A. Locoregional Treatments before Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study from the European Liver Transplant Registry [abstract]. https://atcmeetingabstracts.com/abstract/locoregional-treatments-before-liver-transplantation-for-hepatocellular-carcinoma-a-cohort-study-from-the-european-liver-transplant-registry/. Accessed May 11, 2025.« Back to 2018 American Transplant Congress